SCHEMBL24925839

SCHEMBL24925839

CCC(=O)N1Cc2ccccc2C[C@H]1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.49
OPRD1 P41143 1/20 0.49
OPRK1 P41145 1/20 0.49
ALDH1A1 P00352 3/20 0.48
CHRM2 P08172 1/20 0.46
CHRM4 P08173 1/20 0.46
CHRM1 P11229 1/20 0.46
CHRM3 P20309 1/20 0.46
NOTUM Q6P988 1/20 0.44
ACE P12821 2/20 0.44
PREP P48147 2/20 0.43
HTT P42858 2/20 0.43
MEN1 O00255 1/20 0.43
TSHR P16473 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MTNR1A P48039 1/20 0.43
MTNR1B P49286 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24925818 1.00 OPRM1 (0.49) OPRM1OPRD1OPRK1ALDH1A1CHRM2
SCHEMBL24925917 1.00 OPRM1 (0.49) OPRM1OPRD1OPRK1ALDH1A1CHRM2
SCHEMBL21505456 0.86 OPRM1 (0.48) OPRM1OPRD1OPRK1ALDH1A1CHRM2
SCHEMBL26818022 0.84 KEAP1 (0.47) OPRM1OPRD1OPRK1ALDH1A1NOTUM
SCHEMBL14259830 0.83 NR1D1 (0.43) OPRM1OPRD1OPRK1ACEPREP
SCHEMBL20738530 0.81 NOTUM (0.56) OPRM1OPRD1OPRK1ALDH1A1NOTUM
SCHEMBL15355395 0.81 OPRM1 (0.49) OPRM1OPRD1OPRK1ALDH1A1CHRM2
SCHEMBL20738534 0.81 NOTUM (0.56) OPRM1OPRD1OPRK1ALDH1A1NOTUM
SCHEMBL419149 0.81 NOTUM (0.56) OPRM1OPRD1OPRK1ALDH1A1NOTUM
SCHEMBL24925815 0.81 BCL2 (0.44) OPRM1ACEPREPHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 OPRM1 571/4885OPRD1 1398/4885OPRK1 1001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.